Collate acquires MantleBio
We are thrilled to announce that Collate has acquired MantleBio to accelerate the development of AI solutions for the life sciences.
Collate and MantleBio share a mission for developing technologies that help bring life-saving innovations to patients faster. Together, they are building an AI-first platform that streamlines the life science product lifecycle from concept to market.
About MantleBio
Biotech companies generate vast amounts of complex data: a single DNA sequencing experiment can create 7 TB of files. However, the majority of biotech companies lacked the tools necessary to fully leverage this data.
Founded in 2023, MantleBio developed a modern data engineering platform purpose-built for life sciences. MantleBio's platform enabled research teams to organize and analyze complex biological data in one centralized location while integrating seamlessly with existing research tools like electronic lab notebooks, instruments, and databases. This infrastructure helped teams accelerate discovery by making critical research data more accessible and actionable across the entire organization.
Emily Damato and Madeline Schade founded MantleBio to make the best data engineering technology accessible to all life science research. They brought over a decade of experience in biotech and big tech, including software development at GRAIL, Google, ArsenalBio, MIT, and the Broad Institute.
Following a $5 million funding round led by Y Combinator and Initialized, MantleBio quickly scaled their team and product capabilities. Mantle's platform has helped scientists process complex multi-omics experiments, prepare data for machine learning, and accelerate critical analysis workflows. The platform enabled research teams to focus on discovery, transforming how life science teams perform data-driven research.
AI for Every Step of Life Sciences Innovation
At every step of research and development, life science companies generate tremendous amounts of data and documentation. This administrative burden creates bottlenecks that delay new technologies from reaching patients.
Recent advances in AI technology now make it possible to streamline these processes at scale. Collate leverages artificial intelligence to automate the extensive documentation burdens faced by life science companies. Organizations developing drugs and medical devices require vast amounts of paperwork across their entire operations—from initial research through clinical trials, manufacturing, and regulatory submissions. By applying generative AI to these workflows, companies can significantly reduce manual documentation work and accelerate the timeline for bringing critical treatments to market.
MantleBio's team brings expertise in developing software specifically for life sciences, with deep understanding of the unique challenges that R&D and clinical teams face daily. Their experience building data infrastructure for complex biological research, combined with years working directly with scientists and regulatory requirements, makes them ideal partners in advancing Collate's mission.
Together, we're building AI solutions that understand both the science and the compliance needs of modern life sciences development, accelerating the path from discovery to patients.
Thank You
Thank you to our partners, investors, team, and the scientific community who pursued this mission with us. Together, we will continue to develop technology that helps bring life science innovations to the patients who need them.
Please stay in touch,
Emily Damato
Madeline Schade
Can't wait to see what you guys achieve together!!